CRISPR Gene Editing Technique Featured in Upcoming Myeloma Immunotherapy Trial
A Phase 1 clinical trial that uses the gene editing tool CRISPR to engineer multiple myeloma cellular immunotherapy will soon be underway at the University of Pennsylvania. The small study, which also will enroll patients with other cancer types, aims to create cancer-fighting T-cells with the help of the…